17 patents
Utility
Oxabicycloheptane prodrugs
9 Jan 24
John S. Kovach, Robert A. Volkmann, Anthony Marfat
Filed: 27 Jan 22
Utility
Compositions and Methods for Treating Cancer or Preventing, Inhibiting or Reducing Risk of Metastasis of a Cancer
5 Oct 23
This invention provides compositions of (a) LB-100 or an LB-100 ester, or a pharmaceutically acceptable salt thereof, and (b) a WEE1 kinase inhibitor, checkpoint kinase 1 (“CHK1”) inhibitor, B-cell lymphoma-extra large (“BCL-xL”) inhibitor, BCL-xL proteolysis-targeting chimera (“BCL-xL PROTAC”), pan-BCL inhibitor or ataxia telangiectasia and Rad3-related (“ATR”) inhibitor.
John S. KOVACH, Rene BERNARDS, Matheus Henrique DIAS
Filed: 3 Jan 23
Utility
Oxabicycloheptanes for Treatment of Small Cell Lung Cancer
2 Mar 23
The present invention provides a method of treating a subject suffering from SCLC comprising administering to the subject an effective amount of a PP2A inhibitor and optionally one or more anti-cancer agents.
John S. KOVACH, Ravi SALGIA
Filed: 23 Aug 22
Utility
RepublicationClinical Regimen for Treating Myelodysplastic Syndrome with Phosphatase Inhibitor
13 Oct 22
Alan F. LIST, David A. SALLMAN, John S. KOVACH
Filed: 4 Mar 22
Utility
Oxabicycloheptane Prodrugs
28 Jul 22
John S. KOVACH, Robert VOLKMANN, Anthony MARFAT
Filed: 27 Jan 22
Utility
Clinical Regimen for Treating Myelodysplastic Syndrome with Phosphatase Inhibitor
16 Jun 22
ALAN F. LIST, David A. Sallman, John S. Kovach
Filed: 4 Mar 22
Utility
Oxabicycloheptane prodrugs
1 Feb 22
John S. Kovach, Robert Volkmann, Anthony Marfat
Filed: 5 Feb 20
Utility
Oxabicycloheptanes for Enhancing Car T Cell Function
9 Dec 21
The present invention provides a method of enhancing the function of CAR T cells comprising administering to the CAR T cells a PP2A inhibitor and optionally one or more anti-cancer therapies.
John S. KOVACH, Stephen J. FORMAN, Xiuli WANG
Filed: 13 Jun 19
Utility
Oxabicycloheptanes for Treatment of Secondary Acute Myeloid Leukemia
9 Sep 21
The present invention relates to compounds and methods useful for treating secondary acute myeloid leukemia (sAML).
John S. KOVACH
Filed: 5 Dec 18
Utility
Oxabicycloheptane Prodrugs
14 Oct 20
John S. KOVACH, Robert VOLKMANN, Anthony MARFAT
Filed: 4 Feb 20
Utility
Formulations of Oxabicycloheptanes and Oxabicycloheptenes
10 Jun 20
The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
John S. Kovach, Mickey L. Wells
Filed: 5 Dec 19
Utility
Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
1 Jun 20
John S. Kovach
Filed: 29 Nov 18
Utility
Oxabicycloheptane prodrugs
13 Apr 20
John S. Kovach, Robert Volkmann, Anthony Marfat
Filed: 11 Jun 19
Utility
Oxabicycloheptanes for Modulation of Immune Response
4 Mar 20
The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.
John S. Kovach, Zhengping Zhuang, Sze Chun Winson Ho, Herui Wang, Rongze Lu
Filed: 7 Dec 17
Utility
Formulations of oxabicycloheptanes and oxabicycloheptenes
13 Jan 20
The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
John S. Kovach, Mickey L. Wells
Filed: 7 Apr 14
Utility
Oxabicycloheptane Prodrugs
27 Nov 19
John S. Kovach, Robert Volkmann, Anthony Marfat
Filed: 11 Jun 19
Utility
Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
7 Oct 19
Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
Alan F. List, David A. Sallman, John S. Kovach
Filed: 19 Aug 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first